Oxidative Stress and Inflammation in Heart Disease: Do Antioxidants Have a Role in Treatment and/or Prevention? by Pashkow, Fredric J.
SAGE-Hindawi Access to Research
International Journal of Inﬂammation
Volume 2011, Article ID 514623, 9 pages
doi:10.4061/2011/514623
Review Article
Oxidative Stress and Inﬂammation in Heart Disease:
Do Antioxidants Have a Role in Treatmentand/or Prevention?
Fredric J. Pashkow1,2
1John A. Burns School of Medicine, University of Hawai‘i, Honolulu, HI, USA
2Manoa Innovation Center, 2800 Woodlawn Drive, Honolulu, HI 96822, USA
Correspondence should be addressed to Fredric J. Pashkow, fpashkow@cardaxpharma.com
Received 15 February 2011; Revised 26 April 2011; Accepted 20 June 2011
Academic Editor: Ichiro Manabe
Copyright © 2011 Fredric J. Pashkow. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Inﬂammation triggered by oxidative stress is the cause of much, perhaps even most, chronic human disease including human
aging. The oxidative stress originates mainly in mitochondria from reactive oxygen and reactive nitrogen species (ROS/RNS) and
can be identiﬁed in most of the key steps in the pathophysiology of atherosclerosis and the consequential clinical manifestations of
cardiovascular disease. In addition to the formation of atherosclerosis, it involves lipid metabolism, plaque rupture, thrombosis,
myocardial injury, apoptosis, ﬁbrosis and failure. The recognition of the critical importance of oxidative stress has led to the
enthusiastic use of antioxidants in the treatment and prevention of heart disease, but the results of prospective, randomized
clinical trials have been overall disappointing. Can this contradiction be explained and what are its implications for the discovery/
development of future antioxidant therapeutics?
1.Introduction
While the importance of inﬂammation in illnesses where the
phenomenon is overt, such as following trauma or infection
has been recognized since ancient times, its presence and
crucial role in the manifestation of many diseases never
previously recognized as inﬂammatory is relatively recent.
In such instances, the source of the inﬂammation is also
often imperceptible [1]. This is especially relevant to the
many pervasive chronic diseases that are still responsible
for so much human suﬀering. We are currently achieving
a major understanding of what is involved in the initiation
of the inﬂammatory signaling cascade as well as the com-
plexsignalingpathwaysthemselvesthattranscribeandcoun-
terregulate the molecular messengers (cytokines) that gen-
erate the biological combatants such as the inﬂammatory
enzymes associated with the numerous relevant pathologies.
In this paper we will overview some of the details of our
emerging understanding of inﬂammation and its principal
source, oxidative stress. Further, we will critically review the
historical advocacy of antioxidants for the treatment and
prevention of inﬂammatory-initiating oxidative stress, and
proﬀer explanations for the failure to date of antioxidants
to achieve therapeutic success. Finally, we will discuss the
appropriateness of oxidative stress as a therapeutic target in
cardiovascular disease [2] and the implications this has in us
moving forward in the discovery and development of new
safe and eﬀective cardiovascular drugs.
2. Inﬂammation: A Major Cause
of HumanDisease
While inﬂammation occurring as a consequence of oxidative
stress is not the only biological manifestation of excess
ROS/RNS [3], inﬂammation resulting from oxidative stress
is the cause of much human disease [4]. Typical examples
are dyslipidemia [5], thrombosis [6, 7], metabolic syndrome
[8], type 2 diabetes [9], nonalcoholic steatohepatitis (NASH)
[10–12], macular degeneration [13], and neurodegenerative
diseases such as Alzheimer’s [14]. Inﬂammation is also a
key factor in all aspects of coronary disease including the
initiation and progression of atherosclerotic plaque, plaque
rupture, and thrombosis (atherothrombosis), especially in
recurrent thrombosis where oxidative stress is known to play
a signiﬁcant role [15]( Figure 4), including in those with
normal cholesterol levels and in those being treated with2 International Journal of Inﬂammation
Table 1: Human proof-of-concept studies demonstrating eﬀectiveness of various antioxidant regimens on cardiovascular endpoints.
Study n Intervention Endpoint Antiox Rx results Placebo results P value
SPACE [16] 196 Vit E 800IU/day Composite endpoint1 16% 33% = 0.014
IEISS [17] 125
Vit A 50,000IU/day,
Vit C 1,000mg/day,
Vit E 400mg/day,
β-carotene 25mg/day
Individual component
scores2 20.6 30.6 “Sig. less”
VCE-MI [18] 61 Vit C&E 600mg/day SAECG3 No Δ “Sig. Δ” 3 <0.002
PART [19] 101 Probucol 1,000mg/day Restenosis p PCI 23% 58% = 0.001
ASAP [20] 520 d-alpha-tocopherol 91mg,
Vit C 250mg/day Carotide IMT 0.011mm/year-1 0.020mm/year-1 = 0.008
MVP [21] 317
β-carotene 30,000i.u.,
Vit C 500mg/day,
Vit E 700IU/day,
Probucol 500mg/day
Restenosis p PCI 28.9% 38.9% “Sig. less”
SPACE: Secondary Prevention with Antioxidants of Cardiovascular disease in Endstage renal disease; IEISS: Indian Experiment of Infarct Survival Study;
VCE-MI: Vitamins C&E on Myocardial Infarction; PART: Probucol Angioplasty Restenosis Trial; ASAP: Antioxidant Supplementation in Atherosclerosis
Prevention; MVP: Multivitamins and Probucol Study Group.
1Composite Endpoint: myocardial infarction (fatal and nonfatal), ischemic stroke, non-AV ﬁstular peripheral vascular disease, and unstable angina.
2Individual Component Scores: mean infarct size (creatine kinase and creatine kinase-MB gram equivalents), serum glutamic-oxaloacetic transaminase,
cardiac enzyme lactate dehydrogenase increased, and, QRS score in the electrocardiogram.
3SAECG: Signal-average electrocardiogram components consist of increase in mean QRS and low-amplitude (<40microV) signal durations, a decrease in the
root-mean-square voltage of the last 40ms of the QRS complex.
“statins” and antiplatelet agents. This inﬂammation, caused
by oxidative stress, could be a target for a great next wave of
cardiovascular therapeutics.
3. Role of OxidativeStress
Oxidative stress has been identiﬁed as critical in most of
the key steps in the pathophysiology of atherosclerosis and
acute thrombotic events, including dyslipidemia leading
to atheroma formation, the oxidation of LDL, endothelial
dysfunction, plaque rupture, myocardial ischemic injury,
and recurrent thrombosis (i.e., the secondary, or subsequent
clot that often occurs after initial thrombolysis). The role
of oxidative stress in the connection between the various
coronary disease risk factors such as elevated blood pressure,
diabetes and cigarette smoking, and the clinical sequelae of
disease associated with vasoconstriction, thrombosis, plaque
rupture, and vascular remodeling has been recognized by
Moreno and Fuster [22] but its recognition as a speciﬁc
therapeutic target represents an elevation in its importance
in the oxidative stress hypothesis [23]. Proinﬂammatory
cytokinesarealsoinvolvedincardiacmuscledysfunctionand
in the complex syndrome of heart failure [24–27]. Oxidative
stress has been implicated as well in diabetic cardiomyopathy
[28, 29], congestive cardiomyopathy [30], and hypertensive
heart disease [31].
4.PotentialRole of Antioxidants
Recently, progress has been made regarding the source of
the oxidative stress and an understanding has been achieved
regarding the role of the signaling cascade that moderates
the resulting inﬂammatory process. However, as far back as
the late 1940’s (and perhaps before), antioxidants such as
vitamin E have been suggested as potentially useful in the
treatment of vascular disease [32]. Studies on the inhibition
of experimental cholesterol arteriosclerosis in animals were
published around 1949-1950 and speciﬁc discussions of the
use of vitamin E in the treatment of cardiovascular disease
appeared the same year [33, 34].
Over the years an oxidative stress hypothesis supported
by epidemiologic and observational evidence that encour-
aged belief in and the use of antioxidants [35, 36]. For
example, studies of fruit and vegetable consumption, those
particularly rich in vitamin C and other antioxidants, corre-
lated with a reduction in CVD mortality [37]. Further, the
plasma level of vitamin E was inversely related to mortality
from ischemic heart disease [38]. Numerous observational
studies, such as the Nurses’ Health Study, reported signiﬁ-
cantly reduced risk in those taking vitamin E [39].
5. HumanProof-of-Concept Studies
InitiallyEncouraging
Up to the year 2000, several “smallish” trials using various
combinations of antioxidant vitamins and drugs were
reported as “positive.” This produced optimism in the com-
munity of antioxidant advocates. The conclusions from a
selection of these Phase 2-type studies are summarized in
the remainder of this paragraph and Table 1. In hemodialysis
patients with prevalent cardiovascular disease, supple-
mentation with 800IU/day vitamin E reduced composite
cardiovascular disease endpoints and myocardial infarction
according to Boaz and colleagues in Israel [16]. Singh and
associates reported results from a study in India suggesting
that combined treatment with antioxidant vitamins A, E, C,International Journal of Inﬂammation 3
and beta-carotene in patients with recent acute myocardial
infarction might be protective against cardiac necrosis and
oxidative stress and could be beneﬁcial in preventing com-
plications and in reduction of the cardiac event rate in ACS
patients [17]. Chamiec and colleagues reported results sup-
portingthehypothesisthatinpatientswithAMI,oxygen-free
radical-induced cellular damage contributes to alterations in
electric function of the heart as seen on the signal-averaged
ECG(SAECGs)andthatvitaminsCandEcouldreducethese
alterations [18]. Yokoi et al. reported that probucol admin-
istered beginning 4 weeks before PTCA appears to reduce
subsequent restenosis rates [19]. Salonen et al reported
that combined supplementation with reasonable doses of
both vitamin E and slow-release vitamin C could retard the
progression of common carotid atherosclerosis in men [20].
And ﬁnally, Tardif and his colleagues reported from Montr-
eal that the antioxidant probucol, with or without a combi-
nation of antioxidant vitamins, is eﬀective in reducing the
rate of restenosis after balloon coronary angioplasty [21].
It is important to note that these studies are all fairly
modest in size with the exception of ASAP [20]w h i c h
enrolled more than 500 subjects, and that with the exception
of SPACE [16] ,u s eas u r r o g a t em e a s u r ef o rt h ep r i m a r y
endpoint. Note that all of the therapies tested, again with
the exception of SPACE, involved subgroups where more
than one antioxidant or combinations of therapy were
used. Finally, while the statistical analyses suggest overall
signiﬁcance of the studies’ ﬁndings, only those receiving the
drug probucol with or without multivitamins demonstrated
signiﬁcant eﬀect in the Mutivitamins and Probucol Study
Group [21]. The implications of these observations will be
discussed further below.
6. LargerRandomized Clinical
Trials Unsupportive
But problems developed with the performance of larger
randomized clinical trials [41]. An earlier meta-analysis of
6l a r g e( >1,000 subjects) randomized trials of vitamin E with
pooled data from over 77,000 subjects and 6 trials of β-
carotene in over 131,000 subjects showed that the use of
vitamin E was a “wash” (P = 0.94) (Figure 1(a)) and that
β-carotene use was associated with a worse outcome (P =
0.003) (Figure 1(b))[ 40].
The Cambridge Heart Antioxidant Study (CHAOS)
buoyed hopes for believers in the oxidant stress hypothesis
when it demonstrated a signiﬁcant reduction in nonfatal MI
(P = 0.0001) but oﬀsetting that ﬁnding was an insigniﬁcant
diﬀerenceincardiovasculardeaths(P = 0.78)[42].However,
in a large, long-term trial of male physicians, neither vitamin
E nor vitamin C supplementation reduced the risk of major
cardiovascular events [43]. In women at high risk for CVD
there were no overall eﬀects of ascorbic acid, vitamin E or β-
caroteneoncardiovascularevents[44].Hence,thereisaneed
for a better understanding and more scientiﬁc evidence of
the relative contribution of major nutraceutical constituents
to the inhibition of the progression of atherosclerosis and its
clinical consequences [45].
Studies looking at progression of atherosclerosis using
vitamins E, C or β-carotene have also been inconclusive [47].
However, certain speciﬁc patient populations or clinical
circumstances showed promise: for example, reduction in
the development of transplant atherosclerosis [48]. In acute
coronary syndrome, N-Acetylcysteine (NAC) appeared to
produce a statistically signiﬁcant improvement in cardiac
index in STEMI patients treated with streptokinase and NTG
[49], and in a more recent study, a signiﬁcant reduction of
in-hospital deaths in patients undergoing primary PCI [50].
7.Why the FailureofSoMany
AntioxidantTrials?
Thequestionis,ifoxidativestressissocriticalinthedevelop-
ment and manifestations of coronary heart disease, why is it
that so many of the larger antioxidant trials have failed [52]?
Beforespeciﬁcallyattemptingtoanswerthiscriticalquestion,
let us go back to basics for a moment. The utilization of
oxygen as an integral part of the process for generating
metabolic energy (i.e., mainly via the Electron Transport
Chain or ETC on the inner membrane of the mitochondria)
produces reactive oxygen species (ROS) [53, 54]. These
reactive oxygen species can damage cells or components
of cells by oxidizing DNA or proteins or starting chemical
chain reactions such as lipid peroxidation which incidentally,
occurs mainly inside the bilayer membrane of cells, nuclei,
and mitochondria [55]. ROS can be quite destabilizing to
membrane integrity, but they do have important useful
functions, such as the maintenance of balanced intracellular
redoxsignaling.Thefunctionofantioxidantsystemsisnotto
remove these oxidants entirely, but instead to keep them at a
level below which they will trigger the inﬂammatory cascade,
a series of intracellular and intranuclear signaling that results
in the release of destructive inﬂammatory cytokines [56, 57].
8. Inﬂammation Is Complex
Pathological inﬂammation, a complex whole-cellular path-
way, is a cascade that begins with the production of ex-
cess free radicals that frequently arise from mitochondria
responding to internal or environmental stress and that trig-
ger several signaling steps that endup producing the substan-
ces that actually cause the classical signs of redness, swelling,
and pain in inﬂammation [1]. NF-kappa-B, one of the key
signaling molecules, is a transcription factor that upregulates
the production of downstream inﬂammatory mediators,
including tumor necrosis factor-alpha (TNF-alpha) [58], in-
ducible NO synthase (iNOS), cyclooxygenase-2 (COX-2),
and interleukein-1beta (IL-1beta). Recent studies have sug-
gested that CD40-CD40L interactions themselves regulate
oxidative stress and aﬀect various signaling pathways in both
the immunological and cardiovascular systems [59]. Normal
cellular functions “suckup” these unwanted ROS allowing
the signaling molecules, or cellular pathways such as NF-
kappa-B, to operate normally along with the downstream
products of these pathways, creating a balanced ROS envi-
ronment and normal cellular health.4 International Journal of Inﬂammation
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Figure 1: (a) Meta-analysis of large randomized trials of vit E versus placebo.Meta-analysis of 7 randomized trials involving 77,031 patients
comparing the risk of cardiovascular death among those randomized to placebo or vitamin E (Breslow-Day test, P = 0.73). ATBC: α-
Tocopherol, β-Carotene Cancer Prevention trial; CHAOS: Cambridge Heart Antioxidant Study; CI: Conﬁdence Interval; GISSI – Gruppo
Italiano per lo Studio della Sopravivenza nell’Infarto; HOPE: Heart Ourcomes Prevention Evaluation; HPS: Heart Protection Study; PPP:
Primary Prevention Project, modiﬁed from [40]. (b) Meta-analysis of Randomized Trials of β-carotene versus Placebo. Meta-analysis of 6
randomized trials involving 131,551 patients comparing the risk of cardiovascular death among those randomized to placebo or β-carotene
(Breslow-Daytest,P = 0.12).ATBC:α-Tocopherol,β-CaroteneCancer Prevention trial;CARET:β-Caroteneand Retinol EﬃcacyTrial;HPS:
Heart Protection Study; NSCP: Nambour Skin Cancer Prevention; PHS: Physicians’ Health Study; WHS: Women’s Health Study, modiﬁed
from [40].
9.ErroneousAssumptions Inﬂuenced
TrialDesign
Sowhyhavesomanyantioxidanttherapiesfailedwhentested
in randomized clinical trials? Studies were conducted based
upon epidemiologic ﬁndings of beneﬁt from surveys doc-
umenting increased intake of dietary fruits/vegetables [60].
The well-known biases of such studies aside, the assump-
tion has been that “known” nutritional compounds that is,
vitamin E, vitamin C, and β-carotene, are mainly responsible
for the beneﬁt. The favorable eﬀects shown by some studies
relatingantioxidantdietaryintakeandcardiovasculardisease
may have been exerted by other chemicals present in foods.
Flavonoids, for example, are ideal candidates, since theyInternational Journal of Inﬂammation 5
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Figure 2: Antioxidant activity depends on molecular structure and localization (“Alignment”) in cellular/mitochondrial Membrane. Extent
of deviation in the X-ray crystallographic pattern correlates with an increase in lipid peroxide formation. Correlation between membrane
structure changes and LOOH formation (LOOH, lipid peroxide). Diﬀerences in relative electron density as a function of treatment with
various carotenoids in POPC membranes containing a C/P mole ratio of 0.2. For the peroxidation study, various carotenoids (10μM) were
incorporated into DLPC membranes and underwent lipid peroxidation at 37◦C for 48h. Expressed as percent increase or decrease in LOOH
(lipid peroxide) formation compared to controls containing no carotenoids. ∗P<0.001 versus control; ‡P<0.01 versus control; †P<0.05
versus control; n = 5 ∼ 6. (POPC, 1-palmitoyl 2-oleoyl-3-sn-glycerophosphatidylcholine), adapted from McNulty et al. [46].
are plentiful in foods containing antioxidant vitamins (i.e.,
fruitsandvegetables)andarepotentantioxidants[61].Other
examples include cocoa [62, 63] and the active ingredients in
wine [64, 65].
The na¨ ıve assumption is that all antioxidants are essen-
tially the same. Nothing can be further from the truth. All
antioxidants are not the same: they may work in substan-
tially diﬀerent ways (chain-breaking versus singlet oxygen
quenching, e.g.), and in diﬀerent locations (e.g., in the
bilayer membrane versus the cytoplasm) and very small dif-
ferences in molecular structure can have profound inﬂuence
on biological activity. In the carotenoid family, for example,
distinct eﬀects occur in lipid peroxidation due to mem-
brane structure changes. β-carotene, which misaligns when
localized in the bilayer membrane is highly disruptive struc-
turally and can be functionally pro-oxidant when compar-
ed to structurally similar members of the family that align
completely (Figure 2)[ 46]. These contrasting eﬀects of caro-
tenoids on lipid peroxidation may explain the clinical out-
comes observed in various randomized trials.
10. UnderstandingAntioxidantMode of
Action Is CriticallyImportant
Further,lackofunderstandingofthemodeofaction[66]has
led to erroneous clinical designs and patient selection. Little
attempt was made to scale the antioxidant potential of the
therapy to the underlying oxidative stress. Atherosclerosis is
a multifactorial disease and LDL is oxidized by all major cells
of the arterial wall during the development of atherosclerosis
via more than one mechanism. The various LDL oxidation
pathways produce several lipid peroxidation products such
as isoprostanes from several fatty acids, oxysterols from
unesteriﬁed and esteriﬁed cholesterol, hydroxy fatty acids,
lipid peroxides, and aldehydes. Intervention trials should
be accompanied by measurements of one or more of these
relevant biomarkers at intervals during the study and the
correlation of the biomarkers to the therapeutic intervention
needs to be established. In addition to the markers in use
for lipid peroxidation, there is a need to include markers for
endothelial dysfunction, monocyte adhesion, macrophage
uptake of lipoproteins, thrombotic, and inﬂammatory pro-
cesses [67].
Our recognition of the connection between oxidative
stress, inﬂammatory signaling, and such critical manifes-
tations of atherosclerotic cardiovascular disease as athero-
thrombosis is growing. The cellular membranes of endothe-
lial cells can possess oxidized phospholipids with protruding
sn-2-oxidized fatty acid acyl chains into the extracellular
space. This conformation renders them accessible to interact
with scavenger receptors and other pattern recognition
receptors on the surface of platelets or probing macrophages
of the circulatory and the immune system (Figure 3)[ 51].
Oxidative stress is an important mediator of both ab-
normal platelet function and dysfunctional endothelium-
dependent vasodilation in the setting of cardiovascular dis-
ease. Superoxide anion is an important source of oxidative
stress, has direct eﬀects, and limits the biological activity6 International Journal of Inﬂammation
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Antioxidants may also indirectly inhibit platelets through the metabolism of reactive oxygen species, many of which alter platelet function.
Inﬂammation is linked with the evolution of cardiovascular disease and acute coronary syndromes, adapted from [15].International Journal of Inﬂammation 7
of NO. Excessive vascular superoxide production drives fur-
ther platelet activation and recruitment leading to greater
thrombus formation. The occurrence of superﬁcial intimal
injury caused by endothelial denudation and deep intimal
injury caused by plaque rupture expose collagen and tissue
factor [62] to platelets. Local platelet activation stimulates
further thrombus formation and additional platelet recruit-
ment by supporting cell-surface thrombin formation and
releasing potent platelet agonists such as adenosine diphos-
phate (ADP), serotonin, and thromboxane A2. A thrombus
forms as platelets aggregate via the binding of bivalent
ﬁbrinogen to GP IIb/IIIa. Platelet NO release inﬂuences
platelet recruitment to the growing thrombus and impaired
platelet-derived NO release is likely associated with acute
coronary and stroke syndromes (Figure 4)[ 15]. Thus, anti-
oxidants may indirectly inhibit platelets through scavenging
of reactive oxygen species, many of which alter platelet
function. Despite the diﬀerent subcellular locations of water-
and lipid-soluble antioxidants, these antioxidant pathways in
platelets are closely linked. Antioxidants may also indirectly
inhibit platelets through the metabolism of reactive oxygen
species, many of which directly alter platelet function.
Oxidative stress and inﬂammation are intimately linked
with both the evolution of cardiovascular disease and acute
coronary syndromes. It should be no surprise that ox-LDL
levels show a signiﬁcant positive correlation with the severity
of acute coronary syndromes and that the more severe
lesions also contain a signiﬁcantly higher percentage of ox-
LDL-positive macrophages. Such observations suggest that
increased levels of ox-LDL relate to plaque instability in
human coronary atherosclerotic lesions [68, 69].
11. Dose-Response Documentation Lacking
Implicit in the randomized trials is that the dose of antiox-
idant tested (usually vitamin E), eﬀectively suppressed ox-
idative stress but this was never determined [70]. In fact,
studies suggest that the dosages of the compounds tested
and/or the duration of therapy was not adequate. In one
time-course study, maximum suppression of plasma F2-
isoprostane concentrations did not occur until 16 weeks
of supplementation. In the dose-ranging study there was a
linear trend between the dosage of vitamin E and percentage
reduction in plasma F2-isoprostane concentrations which
reached signiﬁcance at doses of 1600IU (35 ± 2%, P<
0.035) and 3200IU (49 ± 10%, P<0.005) [70]. Whether
such dosages in human subjects would be safe and if the
compound was administered early enough in the lifecycle of
the disease process are other essential considerations.
12. SafetyNow anOverarching Issue
Safety is the overarching issue in drug development today,
butlittlewasdonehistoricallytodetermineiftheantioxidant
being tested for an inﬂammatory-mediated cardiovascular
manifestation is safely tolerated at the levels required to
provide therapeutic relief [71, 72]. Since the high standards
of chemistry, manufacturing, and controls (CMC) required
for pharmaceutical drugs are unlikely to be applied to nutra-
ceutical or dietary-supplement-type products, many of the
questions regarding safety and eﬃcacy of antioxidants will
most likely be answered in the future related to the devel-
opment of proprietary prodrugs seeking regulatory approv-
al. These antioxidant drug candidates, incidentally, will most
likely have greater druglikeness and bioavailability.
13. Conclusion
Despite the lack of signiﬁcant randomized clinical trial data
supporting their use, more than $20b is still being spent
annually on the antioxidant vitamins A, C, and E with more
than 6 million tons of the latter projected to be consumed
annually on a global basis [73]. My belief is that antioxi-
dants because of their provenance as “natural products” or
“nutritional supplements” and their presumption of safety
and eﬃcacy generated from the results of epidemiologic
and observational studies early-on, have not been subjected
to the same stringent developmental requirements that are
applied to new pharmaceutical drug candidates. Biologically
active compounds, formulated properly, administered in
appropriateamountsforanappropriatedurationtotheright
patients will be required to achieve all the requirements that
truly deﬁne therapeutic success.
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